Palones, Esther http://orcid.org/0000-0001-5034-3296
Curto, Elena
Plaza, Vicente
Gonzalez-Quereda, Lidia
Segarra-Casas, Alba
Querol, Luis
Bertoletti, Federico
Rodriguez, María José
Gallano, Pía
Crespo-Lessmann, Astrid
Funding for this research was provided by:
Societat Catalana de Pneumologia
Sociedad Española de Neumología y Cirugía Torácica
Instituto de Salud Carlos III
Centro de Investigación Biomédica en Red de Enfermedades Raras (ACCI ER21P1AC705, ACCI ER21P1AC705)
Ministerio de Universidades (FPU20/06692)
Universitat Autònoma de Barcelona
Article History
Received: 7 August 2023
Revised: 9 September 2023
Accepted: 11 September 2023
First Online: 2 November 2023
Declarations
:
: EP has received conference travel and attendance expenses from Gebro Pharma, Chiesi, FAES Farma, Rovi, GlaxoSmithKline, AstraZeneca, and Sanofi, and funds/grants for research projects from state agencies, non-profit foundations, and Alpha Bioresearch. ECS reports non-financial support from ALK, AstraZeneca, Novartis, and Menarini, personal fees from Boehringer-Ingelheim and TEVA, and personal fees/non-financial support from Chiesi outside the submitted work. VP in the last three years received honoraria for speaking at sponsored meetings from Astrazeneca, Boehringer-Ingelheim, Chiesi, Gebro, GSK, Luminova-Medwell and Sanofi. Received help assistance to meeting travel from Astrazeneca and Chiesi. Act as a consultant for Astrazeneca, Chiesi, GSK and Menarini. LGQ has received conference travel and attendance expenses and fees for talks at meetings sponsored by PTC Therapeutics, and has received funds/grants for research projects from state agencies. PG, LQ, FB, MR and ASC declare that they have no conflicts of interest. AC has received fees in the last 3 years for talks at meetings sponsored by AstraZeneca, Zambón, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, MSD, Novartis, Orion Pharma, and Sanofi, conference travel and attendance expenses from Gebro, GlaxoSmithKline, and Novartis, and funds/grants for research projects from several state agencies, non-profit foundations, AstraZeneca, and GlaxoSmithKline.